.

BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Accenture
Baxter
Harvard Business School
Merck
Teva
Chinese Patent Office
Johnson and Johnson
Express Scripts
UBS

Generated: November 21, 2017

DrugPatentWatch Database Preview

RAYOS Drug Profile

« Back to Dashboard

What is the patent landscape for Rayos, and what generic Rayos alternatives are available?

Rayos is a drug marketed by Horizon Pharma and is included in one NDA. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-eight patent family members in thirty countries.

The generic ingredient in RAYOS is prednisone. There are sixteen drug master file entries for this compound. Fifty-six suppliers are listed for this compound. Additional details are available on the prednisone profile page.
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Horizon Pharma
RAYOS
prednisone
TABLET, DELAYED RELEASE;ORAL202020-001Jul 26, 2012ABRXYesNo► Subscribe► Subscribe ► Subscribe
Horizon Pharma
RAYOS
prednisone
TABLET, DELAYED RELEASE;ORAL202020-003Jul 26, 2012ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Horizon Pharma
RAYOS
prednisone
TABLET, DELAYED RELEASE;ORAL202020-001Jul 26, 2012ABRXYesNo► Subscribe► Subscribe ► Subscribe
Horizon Pharma
RAYOS
prednisone
TABLET, DELAYED RELEASE;ORAL202020-001Jul 26, 2012ABRXYesNo► Subscribe► Subscribe ► Subscribe
Horizon Pharma
RAYOS
prednisone
TABLET, DELAYED RELEASE;ORAL202020-002Jul 26, 2012ABRXYesNo► Subscribe► Subscribe ► Subscribe
Horizon Pharma
RAYOS
prednisone
TABLET, DELAYED RELEASE;ORAL202020-003Jul 26, 2012ABRXYesYes► Subscribe► Subscribe ► Subscribe
Horizon Pharma
RAYOS
prednisone
TABLET, DELAYED RELEASE;ORAL202020-002Jul 26, 2012ABRXYesNo► Subscribe► Subscribe ► Subscribe
Horizon Pharma
RAYOS
prednisone
TABLET, DELAYED RELEASE;ORAL202020-003Jul 26, 2012ABRXYesYes► Subscribe► Subscribe ► Subscribe
Horizon Pharma
RAYOS
prednisone
TABLET, DELAYED RELEASE;ORAL202020-003Jul 26, 2012ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Horizon Pharma
RAYOS
prednisone
TABLET, DELAYED RELEASE;ORAL202020-002Jul 26, 2012ABRXYesNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for RAYOS

Drugname Dosage Strength RLD Submissiondate
prednisoneDelayed-release Tablets1 mg, 2 mg, and 5 mgRayos11/26/2012

Non-Orange Book Patents for Tradename: RAYOS

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,920,838Delayed-release glucocorticoid treatment of rheumatoid disease► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: RAYOS

Country Document Number Estimated Expiration
Hong Kong1130423► Subscribe
Morocco30665► Subscribe
South Africa200509477► Subscribe
Austria512659► Subscribe
Japan2009545546► Subscribe
Eurasian Patent Organization015304► Subscribe
Russian Federation2391093► Subscribe
Russian Federation2005132451► Subscribe
Slovenia2049123► Subscribe
European Patent Office1318816► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Fuji
UBS
Novartis
Mallinckrodt
Argus Health
Teva
Chinese Patent Office
Citi
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot